REVIEW ARTICLE

Biological Sciences
(An International Journal of Medical, Pharmaceutical, and Life Sciences)

Journal home: https://irrespub.com/biolsciences/index.php/1/index



Artificial Intelligence Meets Vascular Health: Identifying Molecules for Precision Repair of Barrier Dysfunctions

Fatima Abdulkadir Muhammad[1*], Shehu-Alimi Elelu[2], Ganiyat Omotayo Ibrahim[3], Idowu Afeez Temitope[4], Miracle Uwa Livinus[5], Abdulsalam Hawau Avoswahi[6], Alege Abdulraheem Lateefat[7], Musa Ojeba Innocent[8], Mustapha Abdulsalam[9]

Department of Microbiology, Skyline University Nigeria[1,1,8,9]; Department of Chemistry, Howard University, Washington DC, USA[2]; Department of Chemistry, Nottingham Trent University, UK[3]; Department of Medicinal Research, Kaohsiung Medical University Hospital, Taiwan[4]; Department of Biochemistry, Skyline University Nigeria[5]; Department of Computer Sciences, University of Ilorin, Nigeria[6]; Department of Microbiology, Kwara State University, Malete, Nigeria[7]

ARTICLE HISTORY

Received: 11-12-2024
Revised: 15-01-2025
Accepted: 04-05-2025
Online: 02-06-2025

KEYWORDS

AI in drug discovery
Vascular barrier repair
Small molecules
Targeted therapeutics
Vascular dysfunction

ABSTRACT

Vascular barrier dysfunctions pose significant health risks, contributing to pathological conditions characterized by increased permeability and inflammation. This study explores the potential of artificial intelligence (AI) in identifying small molecules that can effectively target and repair these dysfunctions. The fundamental mechanisms underlying vascular barrier integrity, common causes of dysfunction, and the role of small molecules in therapeutic repair are discussed. Existing research gaps and limitations of traditional drug discovery approaches necessitating innovative solutions are highlighted. Integrating AI techniques such as machine learning, molecular docking, and virtual screening represents a paradigm shift in drug discovery, offering enhanced efficiency and accuracy in identifying promising candidates. Successful case studies demonstrate the effectiveness of AI-driven methodologies, while challenges related to data limitations and biological validation are also addressed. Looking ahead, the collaboration between AI and multi-omics approaches is poised to transform vascular medicine, facilitating personalized therapeutic strategies and ultimately improving patient outcomes.

*Address for correspondence
Department of Microbiology, Skyline University Nigeria.
Email: nana.a.muhammad@gmail.com
DOI: https://doi.org/10.55006/biolsciences.2025.5205
Published by IR Research Publication; Copyright © 2025 by Authors is licensed under CC BY 4.0

Introduction

The vascular barrier is essential for maintaining tissue homeostasis by regulating the exchange of fluids, nutrients, and cells between the bloodstream and surrounding tissues. It comprises endothelial cells tightly linked to prevent the unregulated passage of substances [1]. The integrity of this barrier is crucial for controlling inflammation and protecting tissues from pathogens and toxins [2]. When the barrier is compromised, it can lead to excessive vascular permeability, edema, and infiltration of inflammatory cells, thus contributing to a range of diseases such as sepsis, acute lung injury,

and chronic inflammatory conditions [3]. Therefore, understanding and maintaining. Vascular barrier function is vital for preventing disease progression and managing conditions that involve vascular damage. Moreover, the need for targeted therapies that can restore barrier integrity in a controlled way has driven interest in molecular therapeutics [4]. Vascular barrier dysfunction arises from various physiological and pathological factors, frequently involving inflammatory responses. Inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, are known to disrupt endothelial junctions, thereby increasing vascular permeability and weakening barrier integrity [5]. Oxidative stress also plays a critical role, as reactive oxygen species (ROS) can damage endothelial cells and their junctions, accelerating barrier breakdown [5]. Infections caused by pathogens, including bacteria and viruses, further compromise the vascular barrier by releasing toxins that damage endothelial cells; a notable example is the severe vascular dysfunction observed in COVID-19 patients, which underscores the impact of viral infections on vascular health [6].

However, aging contributes to barrier dysfunction through chronic low-grade inflammation and elevated oxidative stress, which reduce the resilience of the vascular barrier, rendering elderly individuals more vulnerable to these dysfunctions [7].

Small molecules have emerged as promising candidates for targeting and repairing vascular barrier dysfunctions due to their ability to interact specifically with biological pathways involved in barrier integrity. These molecules can be engineered to restore endothelial junctions, reduce inflammation, and counteract oxidative stress, thereby improving vascular function [8]. For example, compounds targeting endothelial cell receptors, such as S1PR agonists, have shown efficacy in modulating vascular permeability by stabilizing endothelial cell-cell junctions [9]. Similarly, antioxidants like N-acetylcysteine (NAC) counteract oxidative damage, thus helping to maintain endothelial health [10]. AI-based approaches are accelerating the discovery of such molecules by identifying potential therapeutic targets and screening vast libraries of compounds for those with high specificity and efficacy against vascular dysfunctions.

Research Gap and Background

Identified research gaps in vascular barrier repair

Despite advances in understanding vascular biology, significant gaps remain in the ability to effectively repair or restore vascular barrier function in cases of dysfunction. Current therapeutic options primarily focus on managing symptoms rather than addressing the underlying causes of barrier breakdown [11]. A major gap lies in the limited availability of targeted treatments that can specifically reinforce endothelial junctions without triggering adverse immune responses or unwanted systemic effects [11]. Moreover, diseases associated with vascular dysfunctions, such as sepsis, acute respiratory distress syndrome (ARDS), and chronic inflammatory conditions, demand interventions that can act rapidly to restore barrier integrity. However, the current lack of precision therapeutics tailored for acute applications has impeded progress in effective clinical outcomes [12]. Another critical gap is the lack of real-time monitoring and prediction tools for barrier stability, which would enable timely intervention. This gap has driven interest in innovative drug discovery approaches that offer both specificity and rapid-action potential, yet development has been limited by the complexity of vascular biology and the diverse factors contributing to dysfunction [13].

Limitations of traditional drug discovery approaches

Traditional drug discovery methods rely heavily on high-throughput screening (HTS) and empirical testing, which are time-consuming, resource-intensive, and often yield limited success rates in identifying compounds with the necessary specificity for vascular repair [14]. HTS involves testing thousands of compounds against a target in vitro, yet translating these results to in vivo efficacy is challenging, especially for vascular barrier applications that involve dynamic and complex cellular interactions [15]. Furthermore, traditional approaches struggle with identifying therapeutics for multifactorial diseases, as these typically target only single pathways, often leading to reduced efficacy and potential side effects [16]. For instance, targeting vascular dysfunction requires an understanding of the interactions between endothelial cells, immune cells, and extracellular matrix components, making a one-size-fits-all approach ineffective. Moreover, conventional methods often fail to predict off-target effects and toxicity accurately, leading to high attrition rates in clinical trials, where only a fraction of initially promising compounds advance to approval stages [17]. The inefficiency and costliness of traditional methods underscore the need for alternative, data-driven approaches to identify and develop therapeutic compounds efficiently.

Role of AI in addressing these gaps

Artificial Intelligence (AI) offers a promising solution to the limitations of traditional drug discovery, particularly in complex areas like vascular barrier repair. AI-driven approaches can process vast amounts of biochemical, pharmacological, and

clinical data, enabling the identification of promising small.

Molecules with unprecedented accuracy and speed [18]. Machine learning models, for example, can analyze molecular properties and predict interactions between compounds and endothelial targets, thus optimizing lead compounds with high specificity for vascular barrier functions [19]. Moreso, AI-driven techniques such as deep learning and virtual screening can rapidly evaluate large compound libraries, identifying those with the best therapeutic profiles while minimizing adverse effects [20].

AI can also incorporate multi-omics data, integrating genomics, proteomics, and metabolomics to provide a holistic view of vascular barrier dysfunction and to predict which molecules may restore function most effectively. This approach allows researchers to target the repair of specific pathways within endothelial cells, addressing the multifactorial nature of vascular diseases more effectively than traditional methods [21]. By generating precise predictions and facilitating rapid in silico testing, AI reduces time and costs significantly, accelerating the path from discovery to clinical application [22]. Therefore, AI stands as a critical enabler for addressing the identified research gaps in vascular barrier repair, potentially transforming therapeutic development and offering a much-needed alternative to conventional approaches. Figure 1 below represents the significant contributions of artificial intelligence (AI) in enhancing the understanding and treatment of vascular barrier dysfunctions. At its core, the diagram illustrates how AI facilitates four key processes: Data Analysis, Predictive Modelling, Automated Screening, and Personalized Medicine. Each of these processes is linked to specific applications that demonstrate their practical implications. For instance, Data Analysis aids in identifying biomarkers, while Predictive Modelling allows for the simulation of drug interactions. Automated Screening contributes to high-throughput testing, and Personalized Medicine focuses on tailoring therapeutic strategies for individual patients. This structured approach highlights the multifaceted role of AI in bridging existing research gaps and advancing therapeutic interventions in the field of vascular health.



Figure 1. Role of AI in Addressing Research Gaps in Vascular Barrier Dysfunction.

Review of Previous Studies on AI in Vascular Repair

Overview of foundational studies

The integration of artificial intelligence in drug discovery has grown rapidly over the past decade, laying the groundwork for its applications in vascular repair. Early foundational studies primarily used machine learning algorithms to analyze large datasets from genomics, proteomics, and metabolomics, identifying biomarkers relevant to vascular health and dysfunction [23]. Moreso, foundational studies like those conducted by [24] validated the use of AI for screening small molecules and optimizing lead compounds, reducing the time required for target discovery and enabling more specific drug design. These early studies established core principles for leveraging AI in biomedicine, particularly by showing how machine learning and computational approaches could identify molecular structures and interactions with a degree of accuracy that manual methods could not achieve. By focusing on disease-specific applications, researchers began applying these techniques to address vascular dysfunction, thus setting the stage for AI-assisted therapeutic development in this field [24].

Key findings in AI-Assisted small molecule discovery

AI-assisted approaches have produced notable advancements in identifying and developing small molecules for vascular repair, particularly through the use of machine learning algorithms for predicting molecular interactions with endothelial cells. A significant finding is the ability of AI to accelerate virtual screening processes, allowing for the identification of candidate molecules that target specific pathways involved in vascular barrier dysfunctions [25]. Studies have shown that AI algorithms can analyze thousands of compounds for their binding affinity, pharmacokinetics, and toxicity profiles, narrowing down potential therapeutics efficiently [26]. Deep learning models have further improved the specificity of AI-assisted drug discovery. For instance, a study by [27] employed a generative adversarial network (GAN) to design new molecules with properties that favourably interact with vascular endothelium, leading to the development of targeted therapeutics that address endothelial cell junctions specifically. These findings demonstrate that AI's capability to predict molecular efficacy and toxicity profiles not only streamlines the drug discovery process but also improves the precision of small molecule therapies for vascular applications [27].

Progress and limitations in previous research

Despite the considerable progress AI has enabled in identifying small molecules for vascular repair, several limitations remain. Progress in AI-based drug discovery has successfully reduced time and costs, especially in the lead identification phase, by employing virtual screening and predictive modeling techniques. However, while these advancements have improved the early stages of drug development, translating AI-discovered molecules to clinical applications has proven challenging.

One limitation is the dependency on high-quality, diverse datasets. AI models are only as accurate as the data they are trained on, and a lack of comprehensive data on vascular-related pathways can restrict model accuracy [28]. Another constraint is the interpretability of AI models; complex models like deep neural networks are often seen as "black boxes," making it difficult for researchers to understand why certain molecules are prioritized, which can complicate regulatory approvals [29]. Moreso, ethical and regulatory concerns arise due to the reliance on machine-generated predictions, which may have unanticipated effects in vivo. Addressing these limitations requires integrating biological validation at multiple stages and utilizing explainable AI (XAI) techniques to provide clearer insights into how models arrive at predictions. Continued advancements in these areas will be essential to fully leverage AI's potential in discovering effective small-molecule therapies for vascular repair [30].

Artificial Intelligence in Drug Discovery

Overview of AI applications in drug discovery

This study aims to analyze how artificial intelligence has impacted the process of drug discovery through optimization of potential therapeutics identification. In the past, the process of drug discovery has always been very time-consuming and expensive, which may take between ten and fifteen years and nearly three billion dollars on average before a new drug is developed [31]. However, it should be noted that the use of AI may help simplify different stages of drug discovery – targets, hits, leads, and preclinical testing [32]. Another highly relevant use of AI is in predictive analytics: in drug discovery, this is used to model the relationships between a drug and target molecules and biological targets based on prior events [44]. AI architectures can similarly assess big biological data regarding genomics, proteomics, and metabolomics to discover new therapeutic targets and diagnostic markers for ailment. More to this, AI can be useful in clinical trials by providing data relating to patient characteristics that are responsive to given therapies, which in essence will improve the results of the trial as well as diminish costs [35]. Besides, the advancement of AI technologies initiated the discovery of drug repurposing, wherein existing drugs are sought for novel therapeutic applications using molecular and interaction profiles [36]. This approach can bring the development time down and at the same time integrate pre-existing safety data which makes for timely entry of effective treatments into the market. Altogether, AI implementation in drug discovery presents the possibility of increasing efficacy with a meaningful decrease in costs and expediting the availability of new drugs to patients.

Key AI techniques: machine Learning, virtual screening, and molecular docking

AI employs a variety of techniques to facilitate drug discovery, each with its unique applications and advantages:

Machine learning (ML): This core component of AI enables systems to learn from data and improve their predictive capabilities over time. In drug discovery, machine learning algorithms can analyze chemical and biological data to identify patterns that correlate with drug efficacy and toxicity [37]. For instance, supervised learning techniques can be used to classify compounds as active or inactive against a specific target based on known datasets, while unsupervised learning can identify clusters of similar compounds that may share similar biological activities [38].

Virtual screening: This technique involves the computational screening of large libraries of compounds to predict their binding affinity to biological targets. Virtual screening can significantly reduce the number of compounds that need to be synthesized and tested in vitro [39]. By utilizing scoring functions and predictive models, researchers can efficiently identify high-potential candidates for further testing. Virtual screening can be performed using ligand-based or structure-based approaches, depending on the available data and the specific target of interest [40].

Molecular docking: Molecular docking is a computational technique used to predict the preferred orientation of a small molecule (ligand) when it binds to a target protein (receptor). This technique provides insights into the binding affinity and stability of the ligand-receptor complex [41]. Docking algorithms use scoring functions to evaluate how well a ligand fits into the active site of the target protein, which helps prioritize compounds for experimental validation. The integration of molecular docking with machine learning can further enhance the predictive power and accuracy of the drug discovery process [42].

Fig 2 below encapsulates the various artificial intelligence techniques employed in the drug discovery process and their corresponding applications. At the center of the diagram is the main concept of AI Techniques in Drug Discovery, branching out into four primary AI methods: Machine Learning, Deep Learning, Natural Language Processing, and Reinforcement Learning. Each of these techniques is associated with specific applications that highlight their unique contributions to the field. For instance, Machine Learning is linked to predictive analytics and data mining, while Deep Learning focuses on image analysis.



Figure 2. Exploring AI Techniques for Enhanced Drug Discovery.

Benefits of AI in small molecule identification

The application of AI in small molecule identification presents numerous benefits that significantly enhance the drug discovery process:

Increased efficiency: AI algorithms can process and analyze vast datasets quickly, drastically reducing the time required for screening and identification of potential drug candidates [43]. This efficiency allows researchers to explore a larger chemical space than traditional methods would permit.

Improved accuracy: By leveraging complex algorithms and machine learning techniques, AI can achieve a higher level of precision in predicting molecular interactions and biological responses compared to conventional methods. This accuracy minimizes the likelihood of false positives and negatives, ensuring that the most promising candidates are advanced for further testing [44].

Cost reduction: This discovery process has another advantage in the fact that the use of AI means drug development costs are considerably reduced. AI can at least relieve some of the financial pressures felt by pharmaceutical firms because it has the potential to reduce the number of data points that need to be synthesized and tested [45].

Enhanced target discovery: It also helps in identifying different modes of action of the identified compounds or targets as the source of information derived from biological databases may not be easily discernible using objective approaches [46]. This capability is new to drug development and can lead to new solutions for previously intractable diseases.

Facilitation of drug repurposing: AI could assess existing drugs and identify new indications for such drugs hence shifting the current development processes to cheaper and efficient outcomes. This should be especially helpful during viral outbreaks because swift therapeutic interventions are necessary in such situations [47].

Targeting Vascular Barrier Dysfunction with AI-Identified Small Molecules

Mechanisms of vascular barrier repair

Vascular barrier dysfunction is characterized by increased permeability of the endothelial layer, which can lead to edema and various pathological conditions. Understanding the mechanisms of vascular barrier repair is crucial for identifying therapeutic targets.

Endothelial cell junctions: The integrity of the vascular barrier relies heavily on the formation and maintenance of endothelial cell junctions, particularly tight junctions and adherens junctions [48]. These junctions regulate the passage of solutes and cells between the bloodstream and surrounding tissues. Repair mechanisms often involve the reorganization of cytoskeletal elements and the recruitment of specific proteins, such as claudins and occludins, to restore junctional integrity [49].

Inflammatory response modulation: Inflammation plays a critical role in vascular barrier dysfunction, and the repair process often involves modulating inflammatory signalling pathways. For example, anti-inflammatory cytokines like IL-10 can promote endothelial cell survival and barrier function [50]. Moreover, targeting pro-inflammatory cytokines, such as TNF-α and IL-1β, can help in restoring barrier function by reducing the permeability induced by inflammation.

Role of growth factors: Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) are essential for endothelial cell proliferation and migration during the repair process [51]. These growth factors stimulate the regeneration of the endothelial layer and enhance the re-establishment of tight junctions. Therapeutically targeting these growth factor pathways using small molecules could facilitate vascular barrier repair.

Extracellular matrix remodelling: The extracellular matrix (ECM) provides structural support to endothelial cells and influences their behaviour. The repair of the vascular barrier often involves ECM remodelling, which is mediated by matrix metalloproteinases (MMPs) and their inhibitors [52]. Small molecules that modulate MMP activity may play a role in promoting the restoration of the vascular barrier.

Case Studies: successful AI-driven small molecule discoveries

Several case studies highlight the successful application of AI in discovering small molecules that target vascular barrier dysfunction. These discoveries demonstrate the effectiveness of AI-driven methodologies in identifying promising candidates for further development.

Example 1: Identification of VEGF inhibitors

A study by [53] utilized a machine learning approach to identify small molecules that inhibit VEGF signaling pathways, which are known to be involved in vascular permeability. By training a neural network on a dataset of known VEGF inhibitors, the researchers were able to predict novel compounds with high inhibitory activity. These compounds were subsequently validated in vitro, demonstrating their potential to mitigate excessive vascular permeability associated with conditions like diabetic retinopathy.

Example 2: Discovery of ROS scavengers

Another notable case involved the identification of reactive oxygen species (ROS) scavengers that protect endothelial integrity. By employing a virtual screening approach coupled with molecular docking simulations, researchers identified a set of small molecules that could effectively reduce oxidative stress in endothelial cells [53]. The lead compound showed promise in preclinical models by restoring endothelial barrier function compromised by oxidative damage.

Example 3: Novel anti-inflammatory agents

In a recent study, AI-driven drug discovery techniques were used to identify small molecules that act as modulators of inflammatory pathways affecting vascular barriers [54]. The identified compounds were shown to inhibit the production of inflammatory cytokines and promote the recovery of endothelial barrier function in vitro and in vivo. This study illustrates how AI can accelerate the identification of compounds that target complex biological processes.

Translating AI discoveries to vascular applications

While the identification of AI-driven small molecules holds promise, translating these discoveries into practical vascular applications involves several challenges and considerations:

Preclinical and clinical validation: Before AI-identified compounds can be used in clinical settings, extensive preclinical testing is necessary to assess their safety, efficacy, and pharmacokinetics. This process often includes in vitro studies, animal models, and ultimately, human clinical trials [55]. Collaborations between AI researchers and clinical scientists are essential to ensure that the transition from bench to bedside is feasible.

Formulation development: The formulation of small molecules into effective therapeutic agents requires careful consideration of their delivery mechanisms and bioavailability. Techniques such as nanoparticle encapsulation or liposomal formulations may be necessary to enhance the stability and effectiveness of these compounds in vivo [56].

Regulatory pathways: Navigating the regulatory landscape for new therapeutics is complex, particularly for AI-discovered compounds. Regulatory agencies require comprehensive data on the safety and efficacy of new drugs, and AI-generated data may necessitate additional scrutiny to ensure it meets established standards [57]. Engaging with regulatory bodies early in the development process can help streamline this phase.

Integration into clinical practice: Even once a compound is validated, integrating new therapies into clinical practice poses challenges, including physician education, patient acceptance, and healthcare infrastructure adjustments [58]. Effective communication of the benefits and risks associated with new AI-driven therapies will be vital for widespread adoption.

Long-term monitoring and post-market surveillance: After a drug is approved, long-term monitoring for safety and efficacy is essential. This may include collecting real-world data to understand how AI-discovered therapies perform in diverse populations over time [59]. AI can also play a role in post-market surveillance by analyzing data from electronic health records to identify adverse events or long-term outcomes.

Challenges and Limitations in AI-Driven Therapeutics

Data and model limitations in AI for drug discovery

One of the primary challenges in applying AI to drug discovery is the quality and availability of data. Several factors contribute to this issue:

Data quality and variability: AI models rely heavily on high-quality, well-curated datasets for training. In drug discovery, datasets often come from different sources and may vary in quality, leading to inconsistencies and potential biases [60]. Incomplete or erroneous data can result in inaccurate model predictions, hindering the identification of viable drug candidates.

Insufficient diversity in datasets: Many existing datasets are limited in their diversity, which can impact the generalizability of AI models. For instance, most chemical databases may be biased toward a specific set of compounds, which could lead to AI models that perform poorly when applied to novel or diverse chemical spaces [61]. This limitation can result in missed opportunities for discovering effective therapeutics.

Model overfitting: AI models, especially deep learning architectures, are susceptible to overfitting, where the model learns to memorize the training data instead of generalizing from it. This can lead to poor performance on unseen data, reducing the reliability of predictions [62]. Techniques such as cross-validation, regularization, and the use of larger, more diverse datasets can help mitigate this issue.

Interpretability of AI models: Many AI models, particularly complex neural networks, operate as "black boxes," making it difficult to understand how they arrive at specific predictions. This lack of transparency can be a barrier to trust and adoption among researchers and clinicians, who may prefer more interpretable models [63]. Improved interpretability methods are needed to elucidate the decision-making processes of AI systems.

Biological and clinical validation challenges

Once potential drug candidates have been identified using AI, they must undergo rigorous biological and clinical validation, which presents several challenges:

Preclinical testing: Before entering clinical trials, AI-identified compounds must be thoroughly tested in preclinical models, including in vitro assays and animal studies, to assess their safety and efficacy. The translation from in silico predictions to biological effects is not always straightforward, as many factors can influence drug behavior in a living organism [64]. Discrepancies between model systems and human biology can lead to failures in later stages of drug development.

Patient heterogeneity: The biological diversity among patients can significantly impact the efficacy and safety of therapeutics. Factors such as genetic variations, comorbidities, and Environmental influences can affect drug responses [65]. AI models need to account for this heterogeneity to improve

their predictive capabilities in clinical settings, yet creating models that effectively capture such complexity is a daunting task.

Clinical trial design: Designing clinical trials to test AI-identified therapeutics presents unique challenges. Researchers must determine appropriate endpoints, patient populations, and dosing regimens. Moreover, AI-driven approaches may necessitate novel trial designs, such as adaptive trials, which can be complex to implement and analyze [66].

Longitudinal studies: Validating the long-term safety and efficacy of new therapeutics often requires extensive longitudinal studies. These studies can be time-consuming and resource-intensive, potentially delaying the availability of new treatments [67].

autonomy. Patients must be made aware of how AI systems influence their care and the potential implications of these technologies on their treatment [69]. Developing transparent communication strategies will be essential for maintaining trust in AI-driven approaches.

Regulatory frameworks: Current regulatory frameworks for drug approval and medical devices may not be well-suited to address the unique challenges posed by AI technologies. Regulatory agencies need to establish clear guidelines for evaluating AI-driven therapeutics, considering aspects such as data transparency, algorithm validation, and post-market surveillance [70]. Developing these frameworks will be critical for ensuring the safety and efficacy of AI-based therapies.

Table 1. Challenges and Limitations in AI-Driven Therapeutics.

Challenge/ Limitation	Description	Potential Solutions
Data Quality and Availability	Incomplete, biased, or low-quality data can lead to inaccurate predictions and models.	Improving data collection methods and utilizing dataaugmentation techniques.
Model Interpretability	Many AI models, especially deep learning, act as "black boxes," making it difficult to interpret their decisions.	Developing explainable AI (XAI) techniques to enhancetransparency.
Biological and Clinical Validation	The translation of AI predictionsto real-world biological systems can be challenging, leading to high failure rates in clinicaltrials.	Implementing rigorous validation protocols and collaboration with biologists andclinicians.
Regulatory Hurdles	AI-driven therapeutics face stringent regulatory requirementsthat may slow down the approval process.	Engaging with regulatory agencies early in the development process to align on guidelines.
Ethical Considerations	Ethical concerns regarding dataprivacy, consent, and bias in AIalgorithms can hinder research and application.	Establishing ethical frameworksand guidelines for responsible AI use in therapeutics.

Ethical and Regulatory Considerations

The application of AI in drug discovery and therapeutics raises important ethical and regulatory considerations that must be addressed:

Bias and fairness: AI systems can inadvertently perpetuate or exacerbate existing biases in healthcare, particularly if the training data lacks diversity or representation. This can lead to unequal access to effective treatments and exacerbate health disparities [68]. Ensuring fairness and equity in AI applications requires ongoing efforts to identify and mitigate bias in data and algorithms.

Informed consent and patient autonomy: The use of AI in drug discovery and clinical decision-making raises questions about informed consent and patient

Intellectual property issues: The use of AI in drug discovery raises complex intellectual property (IP) questions. For instance, determining ownership of AI-generated discoveries can be challenging, particularly if multiple stakeholders contribute to the development process [71]. Clarifying IP rights in the context of AI-driven therapeutics will be essential for fostering innovation and collaboration in the field.

Liability and accountability: As AI systems take on greater roles in decision-making, questions of liability and accountability arise. Determining who is responsible for adverse outcomes resulting from AI-driven therapeutics—whether it be the AI developers, healthcare providers, or regulatory agencies—remains a critical concern that must be addressed through clear legal frameworks [72].

Future Prospects and Research Directions

Advances in AI and predictive modelling

Recent advancements in AI technology are revolutionizing predictive modeling in drug discovery and vascular medicine. Key developments include:

Deep learning techniques: The development of advanced deep learning models has proven to greatly improve the powers of prediction of small molecules. Predicting molecular properties and interactions has also become a popular application of recent models including convolutional neural networks (CNNs) and recurrent neural networks (RNNs) [73]. These techniques help to use a large set of data and get valuable information about new drugs with more effective results.

Transfer learning: Transfer learning is a promising approach that allows models trained on one task to be adapted for related tasks. This can be particularly beneficial in drug discovery, where data may be scarce for specific compounds. By leveraging existing models trained on large datasets, researchers can accelerate the identification of small molecules for vascular barrier repair [74].

Generative models: Advances in generative modeling techniques, such as Generative Adversarial Networks (GANs) and Variational Autoencoders (VAEs), have opened new avenues for the design of novel compounds. These models can create new molecular structures that optimize desired properties, potentially leading to innovative therapeutics for vascular diseases [75].

Integration of AI with traditional methods: Combining AI-driven approaches with traditional drug discovery techniques can enhance predictive modeling capabilities. For example, using AI to analyze data from high-throughput screening experiments can uncover hidden patterns and lead to more effective candidate selection [76]. This synergistic approach can streamline the drug development process and improve success rates.

Real-time data utilization: The integration of AI with real-time data analytics can enhance predictive modeling in clinical settings. Utilizing data from wearable technologies and electronic health records (EHRs) can provide insights into patient responses and disease progression, enabling more accurate predictions and personalized treatment approaches [77].

Emerging Applications of AI in Personalized Vascular Medicine

AI is paving the way for personalized approaches in vascular medicine, allowing for tailored treatments based on individual patient characteristics. Key emerging applications include:

Patient stratification: AI algorithms can analyze complex datasets to identify patient subgroups that are likely to respond favorably to specific therapies. By utilizing machine learning techniques, researchers can develop predictive models that incorporate genetic, demographic, and clinical data, enabling more precise patient stratification [78]. This approach can improve clinical outcomes by ensuring that patients receive the most suitable treatments based on their unique profiles.

Predictive analytics for treatment response: AI can be used to develop predictive analytics tools that forecast patient responses to various therapies. By analyzing historical patient data, AI models can identify patterns and generate predictions about which patients will benefit from specific vascular treatments, thus optimizing therapeutic strategies [79]. This predictive capability enhances the overall effectiveness of personalized medicine.

Real-time monitoring and intervention: With the rise of telemedicine and remote monitoring technologies, AI applications can facilitate real-time assessment of vascular health. Machine learning algorithms can analyze data from wearable devices to detect changes in physiological parameters, enabling timely interventions and personalized treatment adjustments [80]. This approach not only enhances patient care but also promotes proactive management of vascular conditions.

Integrating multi-omics data: The integration of multi-omics data (genomics, proteomics, metabolomics, etc.) can enhance the understanding of vascular diseases and inform personalized treatment strategies. AI algorithms can analyze these complex datasets to uncover biomarker patterns that are predictive of disease progression and treatment response [81]. By incorporating multi-omics insights, personalized vascular therapies can be developed that target the underlying mechanisms of each patient's condition.

Decision support systems: AI-driven decision support systems can aid clinicians in making personalized treatment decisions. By synthesizing patient data, clinical guidelines, and real-time evidence from ongoing research, these systems can provide tailored recommendations for managing vascular conditions [82]. Such tools can enhance clinical decision-making and improve patient outcomes.

Integrating Multi-Omics for Enhanced Target Identification

The integration of multi-omics data holds significant potential for enhancing target identification in drug discovery and therapeutic development. Key aspects of this integration include:

Comprehensive biological insights: Multi-omics approaches provide a holistic view of biological systems by simultaneously analyzing genomic, transcriptomic, proteomic, and metabolomic data. This comprehensive perspective enables researchers to identify molecular pathways and interactions that contribute to vascular barrier dysfunction, facilitating the discovery of novel therapeutic targets [83].

AI-driven data integration: Advanced AI techniques, such as network analysis and machine learning, can effectively integrate multi-omics data to uncover complex relationships among molecular entities. For instance, unsupervised learning algorithms can identify clusters of co expressed genes and their associated proteins provide insights into shared biological pathways that may be targeted for therapeutic intervention [84].

Biomarker discovery: Multi-omics integration can lead to the identification of novel biomarkers for vascular diseases. By analyzing changes across multiple omics layers in patient samples, researchers can pinpoint specific molecular signatures associated with disease states, aiding in early diagnosis and treatment selection [85]. These biomarkers can serve as critical indicators for monitoring disease progression and therapeutic responses.

Target validation: The combination of multi-omics data can enhance the validation of drug targets by providing complementary evidence from different biological layers. For example, if a specific gene is identified as a potential target, validation can be achieved through transcriptomic analysis (gene expression changes) and proteomic assessment (protein levels) [86]. This multi-faceted validation strengthens the rationale for pursuing specific therapeutic targets.

Precision medicine applications: By combining multi-omics data for precision medicine, successful targeted therapies are achieved in adherence to patient specifications. As treatments can be more personal now that clinicians know the molecular details of patients, side effects can be reduced and advantages increased [87].

Conclusion

This study emphasizes the transformative impact of artificial intelligence (AI) on the identification of small molecules designed to repair vascular barrier dysfunctions. Vascular barrier integrity is essential for maintaining homeostasis, and its impairment can lead to serious health complications. The review identifies common causes of vascular dysfunction, including inflammation, oxidative stress, infections, and aging, highlighting significant research gaps in understanding the mechanisms of vascular barrier repair and the limitations of traditional drug discovery approaches. Addressing these gaps is crucial for developing effective therapeutic strategies. AI is emerging as a powerful tool in drug discovery, employing advanced techniques such as machine learning, molecular docking, and virtual screening to efficiently identify small molecules targeting specific pathways involved in vascular repair. Successful case studies underscore the promise of AI-driven methodologies, demonstrating their potential to accelerate the drug discovery process and enhance therapeutic outcomes. However, challenges remain, including data limitations, biological validation, and ethical considerations, which must be addressed to translate AI discoveries into clinical applications effectively. Looking ahead, the integration of AI into vascular medicine is expected to revolutionize therapeutic approaches. The synergy between AI technologies and traditional biological research will deepen our understanding of the underlying mechanisms of vascular dysfunctions, enabling the identification of novel therapeutic targets and biomarkers. Moreover, advances in AI will facilitate real-time monitoring and personalized interventions, paving the way for precision medicine in vascular health. As researchers continue to explore the frontiers of AI, the potential to improve patient outcomes through targeted therapies for vascular barrier repair remains promising.

Contribution of authors

Fatima Abdulkadir Muhammad conceptualized the study, specifically focusing on the integration of artificial intelligence (AI) for identifying small molecules targeting vascular barrier dysfunction. She also contributed significantly to drafting and revising the manuscript, particularly in the sections related to research gaps and the role of AI in addressing them.

Shehu-Alimi Elelu contributed to the analysis of AI techniques, such as machine learning and molecular docking, and their applications in small molecule discovery. He provided insights into the computational frameworks for virtual screening and molecular design.

Ganiyat Omotayo Ibrahim focused on reviewing the efficiency and mechanisms of small molecule interactions in vascular barrier repair. She contributed to the discussion on the limitations of traditional methods and the advantages of AI-driven drug discovery.

Idowu Afeez Temitope worked on identifying successful case studies of AI-driven small molecule discoveries. He contributed to the analysis of how these molecules can be translated into therapeutic applications targeting vascular health.

Miracle Uwa Livinus explored the mechanisms underlying vascular barrier repair and provided detailed insights into the biological pathways targeted by AI-identified small molecules. She also contributed to discussing the challenges in clinical validation.

Abdulsalam Hawau Avoswahi evaluated the scalability and cost-effectiveness of AI-driven approaches in drug discovery. She also contributed to analyzing data limitations and ethical considerations in AI applications for vascular therapeutics.

Alege Abdulraheem Lateefat focused on the regulatory and commercialization challenges of AI-driven therapeutics. She contributed to discussions on integrating AI into the broader landscape of drug discovery and development.

Musa Ojeba Innocent contributed to reviewing advancements in predictive modeling and multi-omics integration for enhanced target identification. He provided critical feedback on future prospects and emerging applications of AI in vascular health.

Mustapha Abdulsalam discussed the challenges and limitations of AI-driven drug discovery, including data curation and model robustness. He also provided valuable insights into future research directions, particularly on integrating multi-omics and predictive modeling for precision vascular medicine.

Acknowledgments

The authors would like to express their heartfelt gratitude to Professor Senthil A. Kumar, Dean of the School of Science and Information Technology (SSIT) at Skyline University Nigeria, for his invaluable support, guidance, and encouragement throughout this study. His expertise and insightful feedback significantly contributed to the development of this research. The authors also acknowledge the Vice Chancellor of Skyline University Nigeria, whose leadership and provision of a conducive academic environment facilitated the successful completion of this study.

Conflict of Interest

The authors declare no conflicts of interest

Funding

No funding was received for this study

Data Availability

Not available

References

1. Sturtzel, C. Endothelial cells. Immunol. Cardiovasc. Homeost. Pathol. 2017, 71–91.
2. Di Tommaso, N.; Gasbarrini, A.; Ponziani, F.R. Intestinal barrier in human health and disease. Int. J. Environ. Res. Public Health 2021, 18(23), 12836.
3. Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; ... Zhao, L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018, 9(6), 7204.
4. Schoultz, I.; Keita, Å.V. Cellular and molecular therapeutic targets in inflammatory bowel disease—focusing on intestinal barrier function. Cells 2019, 8(2), 193.
5. Guo, X.; Liu, R.; Jia, M.; Wang, Q.; Wu, J. Ischemia-reperfusion injury induced blood-brain barrier dysfunction and the involved molecular mechanism. Neurochem. Res. 2023, 48(8), 2320–2334.
6. He, P.; Talukder, M.H.; Gao, F. Oxidative stress and microvessel barrier dysfunction. Front. Physiol. 2020, 11, 472.
7. Leyane, T.S.; Jere, S.W.; Houreld, N.N. Oxidative stress in aging and chronic degenerative pathologies: molecular mechanisms involved in counteracting oxidative stress and chronic inflammation. Int. J. Mol. Sci. 2022, 23(13), 7273.
8. Incalza, M.A.; D'Oria, R.; Natalicchio, A.; Perrini, S.; Laviola, L.; Giorgino, F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vasc. Pharmacol. 2018, 100, 1–19.
9. Józefczuk, E.; Guzik, T.J.; Siedlinski, M. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol. Res. 2020, 156, 104793.
10. Cepaityte, D.; Leivaditis, K.; Varouktsi, G.; Roumeliotis, A.; Roumeliotis, S.; Liakopoulos, V. N-Acetylcysteine: more than preventing contrast-induced nephropathy in uremic patients—focus on the antioxidant and anti-inflammatory properties. Int. Urol. Nephrol. 2023, 55(6), 1481–1492.
11. Nong, J.; Glassman, P.M.; Muzykantov, V.R. Targeting vascular inflammation through emerging methods and drug carriers. Adv. Drug Deliv. Rev. 2022, 184, 114180.

12. Fountzilas, E.; Tsimberidou, A.M.; Vo, H.H.; Kurzrock, R. Clinical trial design in the era of precision medicine. Genome Med. 2022, 14(1), 101.
13. Ahmed, A.S.I.; Blood, A.B.; Zhang, L. Hypoxia-induced pulmonary hypertension in adults and newborns: implications for drug development. Drug Discov. Today 2024, 104015.
14. Nagarajan, K.; Sundaram, D.P.; Marimuthu, S.K. Innovations in Pharmaceutical Biotechnology. Acad. Guru Publ. House 2024.
15. De Stefano, P.; Bianchi, E.; Dubini, G. The impact of microfluidics in high-throughput drug-screening applications. Biomicrofluidics 2022, 16(3).
16. Anand, U.; Dey, A.; Chandel, A.K.S.; Sanyal, R.; Mishra, A.; Pandey, D.K.; ... de la Lastra, J.M.P. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023, 10(4), 1367–1401.
17. Chi, L.H.; Burrows, A.D.; Anderson, R.L. Can preclinical drug development help to predict adverse events in clinical trials? Drug Discov. Today 2022, 27(1), 257–268.
18. Gangwal, A.; Ansari, A.; Ahmad, I.; Azad, A.K.; Sulaiman, W.M.A.W. Current strategies to address data scarcity in artificial intelligence-based drug discovery: a comprehensive review. Comput. Biol. Med. 2024, 179, 108734.
19. Huang, E.T.; Yang, J.S.; Liao, K.Y.; Tseng, W.C.; Lee, C.K.; Gill, M.; ... Tsai, F.J. Predicting blood-brain barrier permeability of molecules with a large language model and machine learning. Sci. Rep. 2024, 14(1), 15844.
20. Singh, S.; Gupta, H.; Sharma, P.; Sahi, S. Advances in Artificial Intelligence (AI)-assisted approaches in drug screening. Artif. Intell. Chem. 2024, 2(1), 100039.
21. Scioli, M.G.; Storti, G.; D'Amico, F.; Rodríguez Guzmán, R.; Centofanti, F.; Doldo, E.; Orlandi, A. Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. J. Clin. Med. 2020, 9 (6), 1995.
22. Raparthi, M.; Gayam, S.R.; Nimmagadda, V.S.P.; Sahu, M.K.; Putha, S.; Pattyam, S.P.; Kuna, S.S. AI-assisted drug discovery: Emphasizing its role in accelerating precision medicine initiatives and improving treatment outcomes. Hum.-Comput. Interact. Perspect. 2022, 2 (2), 1–10.
23. Saheed, Y.K.; Salau-Ibrahim, T.T.; Abdulsalam, M.; Adeniji, I.A.; Balogun, B.F. Modified bi-directional long short-term memory and hyperparameter tuning of supervised machine learning models for cardiovascular heart disease prediction in the mobile cloud environment. Biomed. Signal Process. Control 2024, 94, 106319.
24. Razzaq, M.; Aslam, M.; Aqeel, M.B.; Malik, M.; Haroon, R.; Kalsoom, U. The Role of Artificial Intelligence in Predicting Cardiovascular Diseases: Current Trends and Future Directions. Azerb. Pharm. Pharmacother. J. 2024, 23, 1–19.
25. AR, N.; GK, R. A deep learning and docking simulation-based virtual screening strategy enables the rapid identification of HIF-1α pathway activators from a marine natural product database. J. Biomol. Struct. Dyn. 2024, 42 (2), 629–651.
26. Gholap, A.D.; Uddin, M.J.; Faiyazuddin, M.; Omri, A.; Gowri, S.; Khalid, M. Advances in Artificial Intelligence in Drug Delivery and Development: A Comprehensive Review. Comput. Biol. Med. 2024, 108702.
27. Duo, L.; Liu, Y.; Ren, J.; Tang, B.; Hirst, J.D. Artificial intelligence for small molecule anticancer drug discovery. Expert Opin. Drug Discov. 2024, 1–16.
28. Du, C.; Zhuang, J.; Huang, X. Deep learning technology in vascular image segmentation and disease diagnosis. J. Intell. Med. 2024.
29. Kırboğa, K.K.; Abbasi, S.; Küçüksille, E.U. Explainability and white box in drug discovery. Chem. Biol. Drug Des. 2023, 102 (1), 217–233.
30. Khera, R.; Oikonomou, E.K.; Nadkarni, G.N.; Morley, J.R.; Wiens, J.; Butte, A.J.; Topol, E.J. Transforming cardiovascular care with artificial intelligence: from discovery to practice: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2024, 84 (1), 97–114.
31. Dickson, M.; Gagnon, J.P. The cost of new drug discovery and development. Discov. Med. 2009, 4 (22), 172–179.
32. Dhudum, R.; Ganeshpurkar, A.; Pawar, A. Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. Drugs Drug Candidates 2024, 3 (1), 148–171.
33. Deng, J.; Yang, Z.; Ojima, I.; Samaras, D.; Wang, F. Artificial intelligence in drug discovery: applications and techniques. Brief. Bioinform. 2022, 23 (1), 430.
34. Abdulsalam, M.; Fatima, Z.Y.U.; Hasiya, U.A.; Ummulkhuthum, A.T.; Aisha, W.N.; Muhammad, F.Y. Deciphering the Genetic Code: Mechanisms, Evolution, and Implications for Biotechnology. World J. Adv. Res. Rev. 2024, 21 (1), 858–868.
35. Abdulsalam, M.; Ila, M.A. Closing the Gap: Artificial Intelligence Integration for Advancing Chikungunya Virus Studies in Africa. Biol. Sci. 2023, 3 (4), 493–502.
36. Abdulsalam, M.; Amina, A.A.; Ummulkhair, A.Y.; Zainab, H.F. Advances in understanding the interplay between Mutagenesis and DNA

repair: Implications for Genomic Stability and Evolution. Int. J. Sci. Acad. Res. 2023, 4 (10), 6428–6438.
37. Staszak, M.; Staszak, K.; Wieszczycka, K.; Bajek, A.; Roszkowski, K.; Tylkowski, B. Machine learning in drug design: Use of artificial intelligence to explore the chemical structure–biological activity relationship. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2022, 12 (2), e1568.
38. Saheed, Y.K.; Balogun, B.F.; Odunayo, B.J.; Abdulsalam, M. Microarray gene expression data classification via Wilcoxon sign rank sum and novel Grey Wolf optimized ensemble learning models. IEEE/ACM Trans. Comput. Biol. Bioinform. 2023, 20 (6), 3575–3587.
39. Lavecchia, A.; Di Giovanni, C. Virtual screening strategies in drug discovery: a critical review. Curr. Med. Chem. 2013, 20 (23), 2839–2860.
40. Vázquez, J.; López, M.; Gibert, E.; Herrero, E.; Luque, F.J. Merging ligand-based and structure-based methods in drug discovery: An overview of combined virtual screening approaches. Molecules 2020, 25 (20), 4723.
41. Sandoval, P.J.; Santiago, J. In vitro analytical approaches to study plant ligand-receptor interactions. Plant Physiol. 2020, 182 (4), 1697–1712.
42. Dara, S.; Dhamercherla, S.; Jadav, S.S.; Babu, C.M.; Ahsan, M.J. Machine learning in drug discovery: a review. Artif. Intell. Rev. 2022, 55 (3), 1947–1999.
43. Pasrija, P.; Jha, P.; Upadhyaya, P.; Khan, M.S.; Chopra, M. Machine learning and artificial intelligence: a paradigm shift in big data-driven drug design and discovery. Curr. Top. Med. Chem. 2022, 22 (20), 1692–1727.
44. Abdulsalam, M.; Hamisu, A.A.; Ahmad, A.M.; Wakili, F.B.; Annu, F.S.; Garba, M.M. Microbiome Dynamics and Strategic Management Strategies: Exploring Synergies between Integrative Medicine Modalities and Microbial Balance. Biol. Sci. 2024, 4 (3), 725–735.
45. Srivastava, N.; Verma, S.; Singh, A.; Shukla, P.; Singh, Y.; Oza, A.D.; Yadav, A.N. Advances in artificial intelligence-based technologies for increasing the quality of medical products. DARU J. Pharm. Sci. 2025, 33 (1), 1–21.
46. You, Y.; Lai, X.; Pan, Y.; Zheng, H.; Vera, J.; Liu, S.; Zhang, L. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct. Target. Ther. 2022, 7 (1), 156.
47. Stawicki, S.P.; Jeanmonod, R.; Miller, A.C.; Paladino, L.; Gaieski, D.F.; Yaffee, A.Q.; Garg, M. The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint American College of Academic International Medicine-world Academic Council of Emergency Medicine multidisciplinary COVID-19 working Group consensus paper. J. Glob. Infect. Dis. 2020, 12 (2), 47–93.
48. Duong, C.N.; Vestweber, D. Mechanisms ensuring endothelial junction integrity beyond VE-cadherin. Front. Physiol. 2020, 11, 519.
49. . Abdulsalam M., Innocent M.O., Livinus M.U., Abdulhakeem A.I., Danjuma F.A., Khadijah A., Tajudeen T.A., Lateefat A.A., Temitope I.A., Adekunle I.J. Community health and vulnerability. In: The interplay of pesticides and climate change: environmental dynamics and challenges. Cham: Springer Nature Switzerland; 2025. p. 443–467.
50. Shao, Y.; Cheng, Z.; Li, X.; Chernaya, V.; Wang, H.; Yang, X.F. Immunosuppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction-a novel mechanism for maintaining vascular function. J. Hematol. Oncol. 2014, 7, 1–14.
51. Neuvians, T.P.; Berisha, B.; Schams, D. Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) expression during induced luteolysis in the bovine corpus luteum. Mol. Reprod. Dev. 2004, 67 (4), 389–395.
52. Raeeszadeh-Sarmazdeh, M.; Do, L.D.; Hritz, B.G. Metalloproteinases and their inhibitors: potential for the development of new therapeutics. Cells 2020, 9 (5), 1313.
53. Wu, X.; Zhang, Q.; Guo, Y.; Zhang, H.; Guo, X.; You, Q.; Wang, L. Methods for the Discovery and Identification of small molecules targeting oxidative stress-related protein-protein interactions: An Update. Antioxidants 2022, 11 (4), 619.
54. Sinha, A.; Roy, S. Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease. Immunopharmacol. Immunotoxicol. 2024, 46 (4), 550–563.
55. Van Norman, G.A. Limitations of animal studies for predicting toxicity in clinical trials: Part 2: Potential alternatives to the use of animals in preclinical trials. Basic Transl. Sci. 2020, 5 (4), 387–397.
56. Eloy, J.O.; de Souza, M.C.; Petrilli, R.; Barcellos, J.P.A.; Lee, R.J.; Marchetti, J.M. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf. B Biointerfaces 2014, 123, 345–363.
57. Gude, S.; Gude, Y.S. The synergy of artificial intelligence and machine learning in revolutionizing pharmaceutical regulatory affairs. Transl. Regul. Sci. 2024, 6 (2), 37–45.
58. Sverdlov, O.; Van Dam, J.; Hannesdottir, K.; Thornton-Wells, T. Digital therapeutics: an

integral component of digital innovation in drug development. Clin. Pharmacol. Ther. 2018, 104 (1), 72–80.
59. Mak, K.K.; Wong, Y.H.; Pichika, M.R. Artificial intelligence in drug discovery and development. Drug Discov. Eval. Saf. Pharmacokinet. Assays 2024, 1461–1498.
60. Abdulsalam, M. Exploring the Therapeutic Promise of Cationic Antibacterial Peptides. Biol. Sci. 2024, 4 (3), 692–700.
61. Vogt, M. Using deep neural networks to explore chemical space. Expert Opin. Drug Discov. 2022, 17 (3), 297–304.
62. Yu, Y.; Chen, Y.; Huang, S.; Wang, R.; Wu, Y.; Zhou, H.; Tan, Z. Enhancing the effluent prediction accuracy with insufficient data based on transfer learning and LSTM algorithm in WWTPs. J. Water Process Eng. 2024, 62, 105267.
63. Evans, R.P.; Bryant, L.D.; Russell, G.; Absolom, K. Trust and acceptability of data-driven clinical recommendations in everyday practice: A scoping review. Int. J. Med. Inform. 2024, 105342.
64. Bugrim, A.; Nikolskaya, T.; Nikolsky, Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov. Today 2004, 9 (3), 127–135.
65. Gervasini, G.; Benítez, J.; Carrillo, J.A. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur. J. Clin. Pharmacol. 2010, 66, 755–774.
66. Askin, S.; Burkhalter, D.; Calado, G.; El Dakrouni, S. Artificial intelligence applied to clinical trials: opportunities and challenges. Health Technol. 2023, 13 (2), 203–213.
67. Musa, I.O.; Isibor, P.O.; Samuel, J.O.; Mustapha, A.; Mustapha, A.; Akande, S.; Adeniji, H. Introduction to Nanotoxicology. In Environmental Nanotoxicology: Combatting the Minute Contaminants; Springer Nature Switzerland: Cham, 2024; pp. 1–22.
68. Esmaeilzadeh, P.; Mirzaei, T.; Dharanikota, S. Patients' perceptions toward human–artificial intelligence interaction in health care: experimental study. J. Med. Internet Res. 2021, 23 (11), e25856.
69. Saheed Y.K., Abdulganiyu O.H., Abdulsalam M., Mustapha M., Olivier M.M., Majikumna K.U. A hybrid ant colony optimization for Parkinson's disease classification based on synthetic minority oversampling and adaptive synthetic techniques. In: 2024 5th International Conference on Data Analytics for Business and Industry (ICDABI); 2024. p. 16–23.
70. Ahmed A.A., Yusuf U.A., Fadlallah Z.H., Innocent M.O., Abdulsalam M. Developing an omics-driven computational framework for next-generation microbiome therapeutics. Biol Sci. 2024;19(4):810–821
71. Abdulsalam, M.; Musa, I.O.; Livinus, M.U.; Elelu, S.A.; Ibrahim, G.O.; Salami, O.L.; Pal, S.K. Blue Bioeconomy and Biomedical Innovation. In Marine Bioprospecting for Sustainable Blue-bioeconomy; Springer Nature Switzerland: Cham, 2024; pp. 143–157.
72. Mennella, C.; Maniscalco, U.; De Pietro, G.; Esposito, M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon 2024.
73. Dou, B.; Zhu, Z.; Merkurjev, E.; Ke, L.; Chen, L.; Jiang, J.; Wei, G.W. Machine learning methods for small data challenges in molecular science. Chem. Rev. 2023, 123 (13), 8736–8780.
74. Abdulsalam, M.; Hamisu, A.A.; Ahmad, A.M.; Wakili, F.B.; Rabiu, I.B.; Burodo, R.A.; Iliyas, N.A. Synergies at the Intersection: Exploring the Role of Bioinformatics in Enhancing Physiotherapy and Nursing Practice. Biol. Sci. 2024, 4 (3), 712–724.
75. Zhao, K.; Zeng, Z.; He, Y.; Zhao, R.; Niu, J.; Sun, H.; Zhou, J. Recent advances in targeted therapy for inflammatory vascular diseases. J. Controlled Release 2024, 372, 730–750.
76. Benavides-Hernández, J.; Dumeignil, F. From Characterization to Discovery: Artificial Intelligence, Machine Learning and High-Throughput Experiments for Heterogeneous Catalyst Design. ACS Catal. 2024, 14 (15), 11749–11779.
77. Dinh-Le, C.; Chuang, R.; Chokshi, S.; Mann, D. Wearable health technology and electronic health record integration: a scoping review and future directions. JMIR mHealth uHealth 2019, 7 (9), e12861.
78. Kalinin, A.A.; Higgins, G.A.; Reamaroon, N.; Soroushmehr, S.; Allyn-Feuer, A.; Dinov, I.D.; Athey, B.D. Deep learning in pharmacogenomics: from gene regulation to patient stratification. Pharmacogenomics 2018, 19 (7), 629–650.
79. Zeb, S.; Nizamullah, F.N.U.; Abbasi, N.; Fahad, M. AI in Healthcare: Revolutionizing Diagnosis and Therapy. Int. J. Multidiscip. Sci. Arts 2024, 3 (3), 118–128.
80. Huang, J.D.; Wang, J.; Ramsey, E.; Leavey, G.; Chico, T.J.; Condell, J. Applying artificial intelligence to wearable sensor data to diagnose and predict cardiovascular disease: a Review. Sensors 2022, 22 (20), 8002.
81. Biswas, N.; Chakrabarti, S. Artificial intelligence (AI)-based systems biology approaches in multi-omics data analysis of cancer. Front. Oncol. 2020, 10, 588221.
82. Ullah, M.; Hamayun, S.; Wahab, A.; Khan, S.U.; Rehman, M.U.; Haq, Z.U.; Naeem, M. Smart technologies are used as smart tools in the

management of cardiovascular disease and their future perspective. Curr. Probl. Cardiol. 2023, 48 (11), 101922.
83. Li, J.; Zheng, M.; Shimoni, O.; Banks, W.A.; Bush, A.I.; Gamble, J.R.; Shi, B. Development of novel therapeutics targeting the blood-brain barrier: from barrier to carrier. Adv. Sci. 2021, 8 (16), 2101090.
84. Hoque, M.N.; Sarkar, M.M.H.; Khan, M.A.; Hossain, M.A.; Hasan, M.I.; Rahman, M.H.; Islam, T. Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: Insights from machine learning and bioinformatics approaches. Front. Immunol. 2022, 13, 918692.
85. Chakraborty, S.; Sharma, G.; Karmakar, S.; Banerjee, S. Multi-OMICS approaches in cancer biology: New era in cancer therapy. Biochim. Biophys. Acta Mol. Basis Dis. 2024, 1870 (5), 167120.
86. Abdulsalam, M.; Salihu, A.T.; Usman, H.Y.; Usman, M.Y. Protein Biosynthesis in Microorganisms: Mechanisms, Regulation, and Biotechnological Applications. World J. Adv. Res. Rev. 2024, 21 (1), 869–881.
87. Yang, C.; Zhang, H.; Zhang, L.; Zhu, A.X.; Bernards, R.; Qin, W.; Wang, C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2023, 20 (4), 203–222.